Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959357 | 0.85 | DPP4 (0.41) | ABCB1ALDH1A1ABCG2ADORA2AADORA2B | |
| SCHEMBL956593 | 0.84 | DPP4 (0.41) | ABCB1ALDH1A1ABCG2METKDM4E | |
| SCHEMBL956372 | 0.84 | FUBP1 (0.39) | ABCB1ALDH1A1ABCG2METKDM4E | |
| SCHEMBL957323 | 0.83 | FFAR1 (0.39) | ABCB1ALDH1A1ABCG2ADORA2AMET | |
| SCHEMBL956154 | 0.81 | FFAR1 (0.40) | ABCB1ALDH1A1ABCG2ADORA2AMET | |
| SCHEMBL955471 | 0.81 | DPP4 (0.38) | ABCB1ALDH1A1ABCG2ADORA2AMET | |
| SCHEMBL959394 | 0.81 | ABCB1 (0.44) | ABCB1ALDH1A1ABCG2ADORA2AADORA2B | |
| SCHEMBL954712 | 0.81 | POLB (0.43) | ABCB1ALDH1A1ABCG2ADORA2AMET | |
| SCHEMBL956808 | 0.80 | DPP4 (0.42) | ABCB1ALDH1A1ABCG2METKDM4E | |
| SCHEMBL959924 | 0.78 | ABCB1 (0.35) | ABCB1ABCG2ADORA2AMETFUBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | ABCB1 649/4885ALDH1A1 1082/4885SIRT1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.